← Eichor
Study identifier: NCT07385001 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

Condition: Esophageal Squamous Cell Carcinoma · Ivonescimab · Neoadjuvant  ·  Sponsor: Tang-Du Hospital

PhasePhase 1/Phase 2
Planned participants45
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma

This description comes directly from the study's public registry record.

Talk to the study team

Xiaolong Yan  ·  +86 15991269383  ·  yanxiaolong@fmmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Tangdu HospitialXi'an, Shannxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07385001